Revilla, Aniceta T.
HRN: 08-96-54 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/08/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
04/08/2025
04/15/2025
IV
4.5g
Q6h
UTI, CAP-MR
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes